Factor V Leiden, prothrombin G20210A substitution and hormone therapy: indications for molecular screening

References

1. Gomes MP, Deitcher SR. Risk of venous thromboembolic disease associated with hormonal contraceptives and hormone replacement therapy: a clinical review. Arch Intern Med 2004; 164:1965–76.10.1001/archinte.164.18.1965Suche in Google Scholar

2. Herrington DM, Klein KP. Invited review: pharmacogenetics of estrogen replacement therapy. J Appl Physiol 2001; 91:2776–84.10.1152/jappl.2001.91.6.2776Suche in Google Scholar

3. Braunstein JB, Kershner DW, Bray P, Gerstenblith G, Schulman SP, Post WS, et al. Interaction of hemostatic genetics with hormone therapy: new insights to explain arterial thrombosis in postmenopausal women. Chest 2002; 121:906–20.10.1378/chest.121.3.906Suche in Google Scholar

4. Kottke-Marchant K. Genetic polymorphisms associated with venous and arterial thrombosis: an overview. Arch Pathol Lab Med 2002; 126:295–304.10.5858/2002-126-0295-GPAWVASuche in Google Scholar

5. Endler G, Mannhalter C. Polymorphisms in coagulation factor genes and their impact on arterial and venous thrombosis. Clin Chim Acta 2003; 330:31–55.10.1016/S0009-8981(03)00022-6Suche in Google Scholar

6. Federici C, Gianetti J, Andreassi MG. Genomic medicine and thrombotic risk: who, when, how and why? Int J Cardiol 2006; 106:3–9.10.1016/j.ijcard.2004.11.038Suche in Google Scholar

7. Schifreen RS, Storts DR, Buller AM. The challenge of using SNPs in the understanding and treatment of disease. Biotechniques 2002; 18:20–1.10.2144/jun0210Suche in Google Scholar

8. Fleming DA. Ethical considerations of genetic testing. J Clin Ethics 2002; 13:316–23.10.1086/JCE200213407Suche in Google Scholar

9. Bates BR, Templeton A, Achter PJ, Harris TM, Condit CM. What does “a gene for heart disease” mean? A focus group study of public understandings of genetic risk factors. Am J Med Genet 2003; 119:156–61.10.1002/ajmg.a.20113Suche in Google Scholar

10. Jordan WM. Pulmonary embolism. Lancet 1961; 2:1146–7.10.1016/S0140-6736(61)91061-3Suche in Google Scholar

11. Rosendaal FR, Helmerhorst FM, Vandenbroucke JP. Female hormones and thrombosis. Arterioscler Thromb Vasc Biol 2002; 22:201–10.10.1161/hq0202.102318Suche in Google Scholar PubMed

12. Jick H, Jick SS, Gurewich V, Myers MW, Vasilakis C. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 1995; 346:1589–93.10.1016/S0140-6736(95)91928-7Suche in Google Scholar

13. Vandenbroucke JP, Rosing J, Bloemenkamp KW, Middeldorp S, Helmerhorst FM, Bouma BN, et al. Oral contraceptives and the risk of venous thrombosis. N Engl J Med 2001; 344:1527–35.10.1056/NEJM200105173442007Suche in Google Scholar PubMed

14. Jick H, Kaye JA, Vasilakis-Scaramozza C, Jick SS. Risk of venous thromboembolism among users of third generation oral contraceptives compared with users of oral contraceptives with levonorgestrel before and after 1995: cohort and case-control analysis. Br Med J 2000; 321:1190–5.10.1136/bmj.321.7270.1190Suche in Google Scholar PubMed PubMed Central

15. Rosendaal FR, Helmerhorst FM, Vandenbroucke JP. Oral contraceptives, hormone replacement therapy and thrombosis. Thromb Haemost 2001; 86:112–23.10.1055/s-0037-1616207Suche in Google Scholar

16. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. J Am Med Assoc 2002; 288:321–33.10.1001/jama.288.3.321Suche in Google Scholar PubMed

17. Grady D, Wenger NK, Herrington D, Khan S, Furberg C, Hunninghake D, et al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/progestin Replacement Study. Ann Intern Med 2000; 132:689–96.10.7326/0003-4819-132-9-200005020-00002Suche in Google Scholar PubMed

18. Herrington DM, Vittinghoff E, Howard TD, Major DA, Owen J, Reboussin DM, et al. Factor V Leiden, hormone replacement therapy, and risk of venous thromboembolic events in women with coronary disease. Arterioscler Thromb Vasc Biol 2002; 22:1012–7.10.1161/01.ATV.0000018301.91721.94Suche in Google Scholar

19. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. J Am Med Assoc 1998; 280:605–13.10.1001/jama.280.7.605Suche in Google Scholar PubMed

20. Herrington DM. The HERS trial results: paradigms lost? Heart and Estrogen/progestin Replacement Study. Ann Intern Med 1999; 131:463–6.10.7326/0003-4819-131-6-199909210-00012Suche in Google Scholar PubMed

21. Renner W, Cichocki L, Forjanics A, Koppel H, Gasser R, Pilger E. G-455A polymorphism of the fibrinogen beta gene and deep vein thrombosis. Eur J Clin Invest 2002; 32:755–8.10.1046/j.1365-2362.2002.01070.xSuche in Google Scholar PubMed

22. Sartori MT, Danesin C, Saggiorato G, Tormene D, Simioni P, Spiezia L, et al. The PAI-1 gene 4G/5G polymorphism and deep vein thrombosis in patients with inherited thrombophilia. Clin Appl Thromb Hemost 2003; 9:299–307.10.1177/107602960300900405Suche in Google Scholar

23. Fatini C, Gensini F, Sticchi E, Battaglini B, Prisco D, Fedi S, et al. ACE DD genotype: an independent predisposition factor to venous thromboembolism. Eur J Clin Invest 2003; 33:642–7.10.1046/j.1365-2362.2003.01185.xSuche in Google Scholar

24. Zidane M, de Visser MC, ten Wolde M, Vos HL, de Monye W, Bertina RM, et al. Frequency of the TAFI –438 G/A and factor XIIIA Val34Leu polymorphisms in patients with objectively proven pulmonary embolism. Thromb Haemost 2003; 90:439–45.10.1160/TH03-01-0035Suche in Google Scholar

25. Komanasin N, Catto AJ, Futers TS, van Hylckama Vlieg A, Rosendaal FR, Ariens RA. A novel polymorphism in the factor XIII B-subunit (His95Arg): relationship to subunit dissociation and venous thrombosis. J Thromb Haemost 2005; 3:2487–96.10.1111/j.1538-7836.2005.01624.xSuche in Google Scholar

26. van Wijk R, Nieuwenhuis K, van den Berg M, Huizinga EG, van der Meijden BB, Kraaijenhagen RJ, et al. Five novel mutations in the gene for human blood coagulation factor V associated with type I factor V deficiency. Blood 2001; 98:358–67.10.1182/blood.V98.2.358Suche in Google Scholar

27. Mingozzi F, Legnani C, Lunghi B, Scanavini D, Castoldi E, Palareti G, et al. A FV multiallelic marker detects genetic components of APC resistance contributing to venous thromboembolism in FV Leiden carriers. Thromb Haemost 2003; 89:983–9.10.1055/s-0037-1613399Suche in Google Scholar

28. Egeberg O. Inherited antithrombin deficiency causing thrombophilia. Thromb Diath Haemorrh 1965; 13:516–30.10.1055/s-0038-1656297Suche in Google Scholar

29. Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369:64–7.10.1038/369064a0Suche in Google Scholar

30. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88:3698–703.10.1182/blood.V88.10.3698.bloodjournal88103698Suche in Google Scholar

31. Rees DC. World distribution of factor V Leiden. Lancet 1995; 346:1133–4.10.1016/S0140-6736(95)91803-5Suche in Google Scholar

32. Tripodi A, Mannucci PM. Laboratory investigation of thrombophilia. Clin Chem 2001; 47:1597–606.10.1093/clinchem/47.9.1597Suche in Google Scholar

33. Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 1995; 85:1504–8.10.1182/blood.V85.6.1504.bloodjournal8561504Suche in Google Scholar

34. Vandenbroucke JP, Koster T, Briet E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994; 344:1453–7.10.1016/S0140-6736(94)90286-0Suche in Google Scholar

35. Bloemenkamp KW, Rosendaal FR, Helmerhorst FM, Buller HR, Vandenbroucke JP. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet 1995; 346:1593–6.10.1016/S0140-6736(95)91929-5Suche in Google Scholar

36. Andersen BS, Olsen J, Nielsen GL, Steffensen FH, Sorensen HT, Baech J, et al. Third generation oral contraceptives and heritable thrombophilia as risk factors of non-fatal venous thromboembolism. Thromb Haemost 1998; 79:28–31.10.1055/s-0037-1614213Suche in Google Scholar

37. Martinelli I, Cattaneo M, Taioli E, De Stefano V, Chiusolo P, Mannucci PM. Interaction between the G20210A mutation of the prothrombin gene and oral contraceptive use in deep vein thrombosis. Arterioscler Thromb Vasc Biol 1999; 19:700–3.10.1161/01.ATV.19.3.700Suche in Google Scholar PubMed

38. Spannagl M, Heinemann LA, Schramm W. Are factor V Leiden carriers who use oral contraceptives at extreme risk for venous thromboembolism? Eur J Contracept Reprod Health Care 2000; 5:105–12.10.1080/13625180008500383Suche in Google Scholar PubMed

39. Wu O, Robertson L, Langhorne P, Twaddle S, Lowe GD, Clark P, et al. Oral contraceptives, hormone replacement therapy, thrombophilias and risk of venous thromboembolism: a systematic review. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) Study. Thromb Haemost 2005; 94:17–25.10.1160/TH04-11-0759Suche in Google Scholar PubMed

40. Rintelen C, Mannhalter C, Ireland H, Lane DA, Knobl P, Lechner K, et al. Oral contraceptives enhance the risk of clinical manifestation of venous thrombosis at a young age in females homozygous for factor V Leiden. Br J Haematol 1996; 93:487–90.10.1046/j.1365-2141.1996.5712013.xSuche in Google Scholar PubMed

41. Lippi G, Manzato F, Brocco G, Franchini M, Guidi G. Prothrombotic effects and clinical implications of third-generation oral contraceptives use. Blood Coagul Fibrinolysis 2002; 13:69–72.10.1097/00001721-200201000-00011Suche in Google Scholar PubMed

42. Rosing J, Tans G, Nicolaes GA, Thomassen MC, van Oerle R, van der Ploeg PM, et al. Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second- and third-generation oral contraceptives. Br J Haematol 1997; 97:233–8.10.1046/j.1365-2141.1997.192707.xSuche in Google Scholar

43. Rosendaal FR, Vessey M, Rumley A, Daly E, Woodward M, Helmerhorst FM, et al. Hormonal replacement therapy, prothrombotic mutations and the risk of venous thrombosis. Br J Haematol 2002; 116:851–4.10.1046/j.0007-1048.2002.03356.xSuche in Google Scholar

44. Lowe G, Woodward M, Vessey M, Rumley A, Gough P, Daly E. Thrombotic variables and risk of idiopathic venous thromboembolism in women aged 45–64 years. Relationships to hormone replacement therapy. Thromb Haemost 2000; 83:530–5.10.1055/s-0037-1613857Suche in Google Scholar

45. Glueck CJ, Wang P, Fontaine RN, Tracy T, Sieve-Smith L, Lang JE. Effect of exogenous estrogen on atherothrombotic vascular disease risk related to the presence or absence of the factor V Leiden mutation (resistance to activated protein C). Am J Cardiol 1999; 84:549–54.10.1016/S0002-9149(99)00375-6Suche in Google Scholar

46. Franco RF, Trip MD, ten Cate H, van den Ende A, Prins MH, Kastelein JJ, et al. The 20210 G→A mutation in the 3′-untranslated region of the prothrombin gene and the risk for arterial thrombotic disease. Br J Haematol 1999; 104:50–4.10.1046/j.1365-2141.1999.01149.xSuche in Google Scholar PubMed

47. De Stefano V, Martinelli I, Mannucci PM, Paciaroni K, Chiusolo P, Casorelli I, et al. The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation. N Engl J Med 1999; 341:801–6.10.1056/NEJM199909093411104Suche in Google Scholar PubMed

48. De Stefano V, Zappacosta B, Persichilli S, Rossi E, Casorelli I, Paciaroni K, et al. Prevalence of mild hyperhomocysteinaemia and association with thrombophilic genotypes (factor V Leiden and prothrombin G20210A) in Italian patients with venous thromboembolic disease. Br J Haematol 1999; 106:564–8.10.1046/j.1365-2141.1999.01613.xSuche in Google Scholar PubMed

49. Martinelli I, Bucciarelli P, Margaglione M, De Stefano V, Castaman G, Mannucci PM. The risk of venous thromboembolism in family members with mutations in the genes of factor V or prothrombin or both. Br J Haematol 2000; 111:1223–9.Suche in Google Scholar

50. Emmerich J, Rosendaal FR, Cattaneo M, Margaglione M, De Stefano V, Cumming T, et al. Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism – pooled analysis of 8 case-control studies including 2310 cases and 3204 controls. Study Group for Pooled-Analysis in Venous Thromboembolism. Thromb Haemost 2001; 86:809–16 (Erratum in: Thromb Haemost 2001;86:1598).10.1055/s-0037-1616136Suche in Google Scholar

51. Legnani C, Palareti G, Guazzaloca G, Cosmi B, Lunghi B, Bernardi F, et al. Venous thromboembolism in young women; role of thrombophilic mutations and oral contraceptive use. Eur Heart J 2002; 23:984–90.10.1053/euhj.2001.3082Suche in Google Scholar PubMed

52. Martinelli I, Sacchi E, Landi G, Taioli E, Duca F, Mannucci PM. High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives. N Engl J Med 1998; 338:1793–7.10.1056/NEJM199806183382502Suche in Google Scholar PubMed

53. Straczek C, Oger E, Beau Yon de Jonage-Canonico M, Plu-Bureau G, Conard J, Meyer G, et al. Estrogen and Thromboembolism Risk (ESTHER) Study Group. Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration. Circulation 2005; 112:3495–500.10.1161/CIRCULATIONAHA.105.565556Suche in Google Scholar PubMed

54. Glueck CJ, Wang P, Fontaine RN, Tracy T, Sieve-Smith L, Lang JE. The effect of exogenous estrogen on atherothrombotic vascular disease risk relates to the presence or absence of the 20210 G/A prothrombin gene mutation: a cross-sectional study of 230 hyperlipidemic women. Circulation 2000; 102:II278–9.Suche in Google Scholar

55. Psaty BM, Smith NL, Lemaitre RN, Vos HL, Heckbert SR, LaCroix AZ, et al. Hormone replacement therapy, prothrombotic mutations, and the risk of incident nonfatal myocardial infarction in postmenopausal women. J Am Med Assoc 2001; 285:906–13.10.1001/jama.285.7.906Suche in Google Scholar PubMed

56. Fermo I, D'Angelo SV, Paroni R, Mazzola G, Calori G, D'Angelo A. Prevalence of moderate hyperhomocysteinemia in patients with early-onset venous and arterial occlusive disease. Ann Intern Med 1995; 123:747–53.10.7326/0003-4819-123-10-199511150-00002Suche in Google Scholar PubMed

57. den Heijer M, Koster T, Blom HJ, Bos GM, Briet E, Reitsma PH, et al. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med 1996; 334:759–62.10.1056/NEJM199603213341203Suche in Google Scholar PubMed

58. den Heijer M, Rosendaal FR, Blom HJ, Gerrits WB, Bos GM. Hyperhomocysteinemia and venous thrombosis: a meta-analysis. Thromb Haemost 1998; 80:874–7.10.1055/s-0037-1615380Suche in Google Scholar

59. Martinelli I, Battaglioli T, Pedotti P, Cattaneo M, Mannucci PM. Hyperhomocysteinemia in cerebral vein thrombosis. Blood 2003; 102:1363–6.10.1182/blood-2003-02-0443Suche in Google Scholar PubMed

60. Haynes WG. Hyperhomocysteinemia, vascular function and atherosclerosis: effects of vitamins. Cardiovasc Drugs Ther 2002; 16:391–9.10.1023/A:1022130217463Suche in Google Scholar

61. Gellekink H, den Heijer M, Heil SG, Blom HJ. Genetic determinants of plasma total homocysteine. Semin Vasc Med 2005; 5:98–109.10.1055/s-2005-872396Suche in Google Scholar PubMed

62. Kang SS, Zhou J, Wong PW, Kowlisyn J, Strokosch G. Intermediate homocysteinemia: a thermolabile variant of methylenetetrahydrofolate reductase. Am J Hum Genet 1988; 48:536–45.Suche in Google Scholar

63. Franco RF, Araujo AG, Guerreiro JF, Elion J, Zago MA. Analysis of the 677 C→T mutation of the methylenetetrahydrofolate reductase gene in different ethnic groups. Thromb Haemost 1998; 79:119–21.10.1055/s-0037-1614230Suche in Google Scholar

64. Key NS, McGlennen RC. Hyperhomocyst(e)inemia and thrombophilia. Arch Pathol Lab Med 2002; 126:1367–75.10.5858/2002-126-1367-HATSuche in Google Scholar PubMed

65. Kluijtmans LA, Den Heijer M, Reitsma PH, Heil SG, Blom HJ, Rosendaal FR. Thermolabile methylenetetrahydrofolate reductase and factor V Leiden in the risk of deep-vein thrombosis. Thromb Haemost 1998; 79:254–8.10.1055/s-0037-1614974Suche in Google Scholar

66. Domagala TB, Adamek L, Nizankowska E, Sanak M, Szczeklik A. Mutations C677T and A1298C of the 5,10-methylenetetrahydrofolate reductase gene and fasting plasma homocysteine levels are not associated with the increased risk of venous thromboembolic disease. Blood Coagul Fibrinolysis 2002; 13:423–31.10.1097/00001721-200207000-00007Suche in Google Scholar

67. Zalavras ChG, Giotopoulou S, Dokou E, Mitsis M, Ioannou HV, Tzolou A, et al. Lack of association between the C677T mutation in the 5,10-methylenetetrahydrofolate reductase gene and venous thromboembolism in Northwestern Greece. Int Angiol 2002; 21:268–71.Suche in Google Scholar

68. Morelli VM, Lourenco DM, D'Almeida V, Franco RF, Miranda F, Zago MA, et al. Hyperhomocysteinemia increases the risk of venous thrombosis independent of the C677T mutation of the methylenetetrahydrofolate reductase gene in selected Brazilian patients. Blood Coagul Fibrinolysis 2002; 13:271–5.10.1097/00001721-200204000-00014Suche in Google Scholar

69. Ray JG, Langman LJ, Vermeulen MJ, Evrovski J, Yeo EL, Cole DE. Genetics University of Toronto Thrombophilia Study in Women (GUTTSI): genetic and other risk factors for venous thromboembolism in women. Curr Control Trials Cardiovasc Med 2001; 2:141–9.10.1186/CVM-2-3-141Suche in Google Scholar

70. Varela ML, Adamczuk YP, Forastiero RR, Martinuzzo ME, Cerrato GS, Pombo G, et al. Major and potential prothrombotic genotypes in a cohort of patients with venous thromboembolism. Thromb Res 2001; 104:317–24.10.1016/S0049-3848(01)00384-XSuche in Google Scholar

71. Frederiksen J, Juul K, Grande P, Jensen GB, Schroeder TV, Tybjaerg-Hansen A, et al. Methylenetetrahydrofolate reductase polymorphism (C677T), hyperhomocysteinemia, and risk of ischemic cardiovascular disease and venous thromboembolism: prospective and case-control studies from the Copenhagen City Heart Study. Blood 2004; 104:3046–51.10.1182/blood-2004-03-0897Suche in Google Scholar PubMed

72. Den Heijer M, Lewington S, Clarke R. Homocysteine, MTHFR and risk of venous thrombosis: a meta-analysis of published epidemiological studies. J Thromb Haemost 2005; 3:292–9.10.1111/j.1538-7836.2005.01141.xSuche in Google Scholar PubMed

73. Sidney S, Petitti DB, Soff GA, Cundiff DL, Tolan KK, Quesenberry CP Jr. Venous thromboembolic disease in users of low-estrogen combined estrogen-progestin oral contraceptives. Contraception 2004; 70:3–10.10.1016/j.contraception.2004.02.010Suche in Google Scholar PubMed

74. Brown CA, McKinney KQ, Young KB, Norton HJ. The C677T methylenetetrahydrofolate reductase polymorphism influences the homocysteine-lowering effect of hormone replacement therapy. Mol Genet Metab 1999; 67:43–8.10.1006/mgme.1999.2847Suche in Google Scholar PubMed

75. Tanis BC, Blom HJ, Bloemenkamp DG, van den Bosch MA, Algra A, van der Graaf Y, et al. Folate, homocysteine levels, methylenetetrahydrofolate reductase (MTHFR) 677C→T variant, and the risk of myocardial infarction in young women: effect of female hormones on homocysteine levels. J Thromb Haemost 2004; 2:35–41.10.1111/j.1538-7836.2004.00508.xSuche in Google Scholar PubMed

76. Bloemenkamp KW, Rosendaal FR, Helmerhorst FM, Vandenbroucke JP. Higher risk of venous thrombosis during early use of oral contraceptives in women with inherited clotting defects. Arch Intern Med 2000; 160:49–52.10.1001/archinte.160.1.49Suche in Google Scholar

77. Konkle BA, Schafer AI. Hemostasis, thrombosis, fibrinolysis, and cardiovascular disease. In: Zipes D, Libby P, Bonow R, Branuwald E, editors. Braunwald's heart disease, 7th ed. Philadelphia, PA: Elsevier-Saunders, 2005:2067–92.Suche in Google Scholar

78. Grody WW, Griffin JH, Taylor AK, Korf BR, Heit JA, ACMG Factor V Leiden Working Group. American College of Medical Genetics consensus statement on factor V Leiden mutation testing. Genet Med 2001; 3:139–48.10.1097/00125817-200103000-00009Suche in Google Scholar

79. Kujovich JL. Hormones and pregnancy: thromboembolic risks for women. Br J Haematol 2004; 126:443–54.10.1111/j.1365-2141.2004.05041.xSuche in Google Scholar

80. Mannucci PM. Laboratory detection of inherited thrombophilia: a historical perspective. Semin Thromb Hemost 2005; 31:5–10.10.1055/s-2005-863799Suche in Google Scholar

81. Hertzberg MS. Genetic testing for thrombophilia mutations. Semin Thromb Hemost 2005; 31:33–8.10.1055/s-2005-863803Suche in Google Scholar

82. Cosmi B, Coccheri S. Thrombophilia in young women candidate to the pill: reasons for and against screening. Pathophysiol Haemost Thromb 2002; 32:315–7.10.1159/000073588Suche in Google Scholar

83. Wu O, Robertson L, Twaddle S, Lowe G, Clark P, Walker I, et al. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) Study. Screening for thrombophilia in high-risk situations: a meta-analysis and cost-effectiveness analysis. Br J Haematol 2005; 131:80–90.10.1111/j.1365-2141.2005.05715.xSuche in Google Scholar

84. Martinelli I, De Stefano V, Taioli E, Paciaroni K, Rossi E, Mannucci PM. Inherited thrombophilia and first venous thromboembolism during pregnancy and puerperium. Thromb Haemost 2002; 87:791–5.10.1055/s-0037-1613085Suche in Google Scholar

85. Kupferminc MJ, Eldor A, Steinman N, Many A, Bar-Am A, Jaffa A, et al. Increased frequency of genetic thrombophilia in women with complications of pregnancy. N Engl J Med 1999; 340:9–13.10.1056/NEJM199901073400102Suche in Google Scholar

86. Blumenfeld Z. Thrombophilia-associated pregnancy wastage. Fertil Steril 1999; 72:765–74.10.1016/S0015-0282(99)00360-XSuche in Google Scholar

87. Caprini JA, Glase CJ, Anderson CB, Hathaway K. Laboratory markers in the diagnosis of venous thromboembolism. Circulation 2004; 109:I4–8.10.1161/01.CIR.0000122869.59485.36Suche in Google Scholar PubMed

88. Dahlback B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C. Prediction of a cofactor for activated protein C. Proc Natl Acad Sci USA 1993; 90:1004–8.10.1073/pnas.90.3.1004Suche in Google Scholar PubMed PubMed Central

89. Tripodi A, Mannucci PM. Laboratory investigation of thrombophilia. Clin Chem 2001; 47:1597–606.10.1093/clinchem/47.9.1597Suche in Google Scholar